SEI Investments’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

SEI Investments’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-6,053	Closed	-$26K	–	2923
2019 Q1	$26K	Sell	6,053 -20,043	-77%	-$90.7K	﹤0.01%	2718
2018 Q4	$110K	Buy	26,096 +26,033	+41,322%	+$133K	﹤0.01%	2178
2018 Q3	$0	Buy	+63	New	+$484	﹤0.01%	3702
2017 Q3	–	Sell	-39,599	Closed	-$269K	–	3489
2017 Q2	$269K	Buy	+39,599	New	+$292K	﹤0.01%	1801
2017 Q1	–	Sell	-31,900	Closed	-$276K	–	3145
2016 Q4	$276K	Buy	+31,900	New	+$236K	﹤0.01%	1717

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SEI Investments's PGNX Position: Q2 2019 in Review

SEI Investments sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2019, closing a stake of 6,053 shares — an estimated $26K sold.

SEI Investments first reported a position in PGNX in Q4 2016 and held it in 5 quarters. The position peaked at $276K in Q4 2016. 142 funds tracked by Wall St. Rank hold PGNX as of Q2 2019.

SEI Investments reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2019 after selling out during the quarter.
SEI Investments sold 6,053 Progenics Pharmaceuticals Inc shares in Q2 2019, an estimated $26K.
SEI Investments first reported a position in Progenics Pharmaceuticals Inc in Q4 2016 and held it in 5 quarters.
SEI Investments's Progenics Pharmaceuticals Inc position peaked at $276K in Q4 2016.
142 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2019.

Based on SEI Investments's 13F filing for Q2 2019, filed 14 Aug 2019.